Gastric or esophagogastric junction cancer (GC/EGJC) is the third leading cause of cancer-related deaths worldwide, with most of the cases diagnosed at late stages (1,2). For patients (pts) with unresectable… Click to show full abstract
Gastric or esophagogastric junction cancer (GC/EGJC) is the third leading cause of cancer-related deaths worldwide, with most of the cases diagnosed at late stages (1,2). For patients (pts) with unresectable or recurrent advanced GC/EGJC, systemic chemotherapy is the most important method used to prolong survival (3). However, research data indicate that the objective response rate (ORR) ranges from 6.8–25% and the progression-free survival (PFS) was 1.5–5.3 months in second or further lines therapy (4-6), Original Article
               
Click one of the above tabs to view related content.